At a glance
| Attribute | Saxenda | Contrave |
|---|---|---|
| Form | Daily injection | Twice-daily tablet |
| How often | Daily injection | Twice-daily oral tablet — no injection |
| Weight loss in trials | Up to 8% — SCALE Obesity and Prediabetes (56 weeks) | Up to 9.3% — COR-BMOD (56 weeks) |
| FDA approved | 2014 | 2014 |
| Made by | Novo Nordisk | Currax Pharmaceuticals |
| How it works | A GLP-1 analogue with a half-life of approximately 13 hours (requiring daily injection). | Bupropion activates appetite-suppressing nerve cells in the brain's hunger control centre (the hypothalamus). |
| Monthly cost, self-pay | $1,000–$1,349/mo | $100–$400/mo |
| Most reported reaction | Nausea 40% (SCALE Obesity and Prediabetes) | Nausea 33% (COR-I) |
Weight loss in each drug's main trial
No head-to-head trial has compared these two drugs.
SCALE Obesity and Prediabetes (56 weeks)
COR-BMOD (56 weeks)
In clinical trials, participants taking liraglutide lost on average up to 8% of their starting body weight, and participants taking naltrexone / bupropion ER lost on average up to 9.3%. Those numbers come from two different studies: SCALE Obesity and Prediabetes enrolled 3,731 adults with obesity or overweight with comorbidities over 56 weeks against placebo, while COR-BMOD enrolled adults with obesity, with intensive behaviour therapy over 56 weeks against placebo + intensive behaviour therapy. Who took part, how long each trial ran and what each drug was measured against all move the percentage, so the two figures are not a measured difference between the drugs.
Monthly cost, self-pay
The bar spans the range in each drug's price record — lowest listed price to highest.
Brand (Saxenda) ~$1,000–$1,349/month. Generic liraglutide is typically $135–$200 less than brand.
~$100–$400/month (brand). Generic available in some markets.
Side effects reported in the trials
Both trials reported 3 reactions in common. Each rate is the percentage of participants who reported it in the trial named beside it, so the two columns are not from the same study.
How they differ in practice
How you take it
- Saxenda — Once-daily subcutaneous injection
- Contrave — Oral extended-release tablet, twice daily
Dose build-up
- Saxenda — 0.6 mg → 3.0 mg, escalated over 4 weeks
- Contrave — titrated to 32/360 mg/day over 4 weeks
Where a drug is not listed here, its prescribing information sets out its own dose steps.
How soon it acts
- Saxenda — Effects visible within 4–8 weeks; maximum benefit typically by 56 weeks
- Contrave — Appetite and craving changes typically within 4–8 weeks; significant weight loss by 16–24 weeks
Heart and metabolic findings
- Saxenda — The LEADER trial, in type 2 diabetes, showed cardiovascular benefit.
- Contrave — The LIGHT cardiovascular outcomes trial was stopped early, because of a protocol violation.
As stated in each drug’s trial record — not a claim about which drug protects the heart more.
Other findings recorded
- Saxenda — Approved for adolescents aged 12 and over (SCALE teens programme); generic liraglutide now available (Teva, August 2025) — reducing out-of-pocket cost
- Contrave — May help specifically with emotional eating and food cravings; bupropion's antidepressant effect may be beneficial if low mood contributes to overeating
If you stop taking it
- Saxenda — Weight regain after stopping is expected, as with other GLP-1 drugs.
- Contrave — Weight regain after stopping is expected.
Common questions
Written and maintained by one person · Built with agentic AI tools · Every number checked against the cited trial · Not medical advice
Clinical evidence — Liraglutide and Naltrexone / Bupropion ER
No head-to-head trial has compared these two drugs.
- SCALE Obesity and Prediabetes — Liraglutide: 3,731 adults with obesity or overweight with comorbidities, 56 weeks. New England Journal of Medicine, 2015. View source ↗
- COR-BMOD — Naltrexone / Bupropion: Adults with obesity, with intensive behaviour therapy, 56 weeks. Obesity, 2011. View source ↗
- COR-I — Naltrexone / Bupropion: 1,742 adults with obesity or overweight with comorbidities, 56 weeks. The Lancet, 2010. View source ↗
- Saxenda (liraglutide) — FDA prescribing information — DailyMed View source ↗
- Contrave (naltrexone and bupropion extended-release) — FDA prescribing information — DailyMed View source ↗
Next step most people take
Built with agentic AI tools and not a substitute for medical advice
Last reviewed: